Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.30 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.30 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13545301 | 0.89 | TRPV1 (0.51) | TRPV1ALDH1A1MAPTRAB9AGFER | |
| SCHEMBL13545300 | 0.89 | TRPV1 (0.42) | TRPV1ALDH1A1MAPTRAB9AGFER | |
| SCHEMBL13383402 | 0.87 | TRPV1 (0.54) | TRPV1 | |
| SCHEMBL13545280 | 0.84 | TRPV1 (0.36) | TRPV1ALDH1A1MAPTRAB9AGFER | |
| SCHEMBL3588363 | 0.82 | TRPV1 (0.36) | TRPV1DDB1CRBNCHEK1PARP1 | |
| SCHEMBL3588367 | 0.82 | CA9 (0.41) | TRPV1MAPTDDB1CRBNCHEK1 | |
| SCHEMBL13545283 | 0.81 | ALDH1A1 (0.37) | TRPV1ALDH1A1MAPTRAB9AGFER | |
| SCHEMBL13545282 | 0.79 | TRPV1 (0.45) | TRPV1ALDH1A1MAPTRAB9AGFER | |
| SCHEMBL13382932 | 0.78 | TRPV1 (0.34) | TRPV1ALDH1A1MAPTRAB9AGFER | |
| SCHEMBL13382926 | 0.77 | S1PR1 (0.35) | TRPV1RAB9ADDB1CRBNPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | CCNY, CCND3, NSD3 | TRPV1 2518/4885ALDH1A1 1904/4885MAPT 4758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.